Bone Biologics Corp Reports Officer/Director Changes
Ticker: BBLGW · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election
Related Tickers: BBLG
TL;DR
Bone Biologics filed an 8-K on Oct 1st about director/officer changes. Watch for details.
AI Summary
Bone Biologics Corporation filed an 8-K on October 4, 2024, reporting events as of October 1, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding these changes were not provided in the excerpt.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key leadership and officer compensation can indicate internal shifts that may impact future performance.
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- October 1, 2024 (date) — Earliest event date
- October 4, 2024 (date) — Filing date
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific names and details are not provided in this excerpt.
What is the exact date of the earliest reported event?
The earliest event reported is as of October 1, 2024.
When was this 8-K form filed?
This 8-K form was filed on October 4, 2024.
What are the main topics covered in this 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the company's principal business address?
The principal business address is 2 BURLINGTON WOODS DRIVE, SUITE 100, BURLINGTON, MA 01803.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 12.9 · Accepted 2024-10-04 17:00:41
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-039554.txt ( ) — 260KB
- bblg-20241001.xsd (EX-101.SCH) — 4KB
- bblg-20241001_def.xml (EX-101.DEF) — 29KB
- bblg-20241001_lab.xml (EX-101.LAB) — 36KB
- bblg-20241001_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: October 4, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer